INTRODUCTION AND OBJECTIVES: Genome-wide association studies identified or confirmed 15 genomic regions that modulate urinary bladder cancer risk. Little is known whether these genetic variants interact to increase bladder cancer risk. Furthermore, it is likely that different polymorphisms are relevant in smokers and non-smokers. Therefore, we conducted an interaction analysis comprising 12 susceptibility variants and totally 5049 cases and 5452 controls.
METHODS: Recently, we identified two-and three-variant combinations associated with a particular increase of bladder cancer risk in a urinary bladder cancer case-control series (Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), 1501 cases, 1565 controls). In an independent case-control series (Nijmegen Bladder Cancer Study, NBCS, 1468 cases, 1720 controls) we confirmed these two-and three-variant combinations. Pooled analysis of the two studies as discovery group (IfADo-NBCS) resulted in sufficient statistical power to test up to four-variant combinations by a logistic regression approach. The New England and Spanish Bladder Cancer Studies (2080 cases and 2167 controls) were used as a replication series. Twelve previously identified risk variants were considered.
RESULTS: The strongest four-variant combination was obtained in never smokers. The combination of rs1014971[AA] near apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A) and chromobox homolog 6 (CBX6), solute carrier family 1s4 (urea transporter), member 1 (Kidd blood group) (SLC14A1) exon single nucleotide polymorphism (SNP) rs1058396 [AG, GG] , UDP glucuronosyltransferase 1 family, polypeptide A complex locus (UGT1A) intron SNP rs11892031[AA] and rs8102137[CC, CT] near cyclin E1 (CCNE1) resulted in an unadjusted odds ratio (OR) of 2.59 (95% CI ¼ 1.93-3.47; P ¼ 1.87 x 10 -10 , while the individual variant ORs ranged only between 1.11 and 1.30. The combination replicated in the New England and Spanish Bladder Cancer Studies (OR unadjusted ¼ 1.60, 95% CI ¼ 1.10-2.33; P ¼ 0.013). The four-variant combination is relatively frequent, with 25% in never smoking cases and 11% in never smoking controls (total study group: 19% cases, 14% controls).
CONCLUSIONS: In conclusion, we show that four high-risk variants can statistically interact to confer increased bladder cancer risk particularly in never smokers. 
MP54-12 MOLECULAR CHARACTERIZATION OF N-METHYL-N-NITROSOUREA-INDUCED BLADDER UROTHELIAL TUMOR IN RATS
Takahiro Yoshida*, Alexander Baras, Max Kates, Nikolai Sopko, Xiaopu Liu, Gregory Joice, David McConkey, Trinity Bivalacqua, Baltimore, MD INTRODUCTION AND OBJECTIVES: Human bladder cancer has recently been characterized based on RNA/protein expression and genomic alterations, indicating intrinsic subtypes of the disease associated with prognosis and response to systemic therapy. Meanwhile, Nmethyl-N-nitrosourea (MNU)-induced bladder tumor in rodents are widely used for study of human bladder cancer. Although the model mimics papillary morphology and step-wise progression of human bladder cancer, little is known about molecular similarities to human bladder cancer. In this study, we characterized MNU-induce bladder tumor in rats using immunohistochemistry, qRT-PCR, and RNA sequencing.
METHODS: Fisher 344 rats at age of 7 weeks intravesically received 4 doses of 1.5mg/kg MNU. Animals were sacrificed at week 16 and 30, and bladders were processed for pathological evaluation. RNA was also extracted from normal urothelium and cancerous area in paraffin embedded tissue, and subjected to qRT-PCR and RNA sequencing. Sequencing data was analyzed with publicly available dataset of human bladder cancer.
RESULTS: At week 16, all rats were found to have non-muscle invasive bladder tumor. Rats developed 5-10-mm, protruding tumors in their bladders at week 30. H&E staining showed MNU-induced tumors were histologically similar to human papillary bladder tumors. Three out of 6 bladders at week 30 showed muscle invasion. Immunohistochemistry and qRT-PCR revealed enrichment of basal markers in MNU tumors compared to normal urothelium, while maintaining luminal markers. Analysis of sequencing data showed that MNU tumors were clustered with human luminal tumors with upregulation of FGFR3 signature.
CONCLUSIONS: Combination of immunohistochemistry, qRT-PCR, and RNA sequencing demonstrated that MNU-induced tumor was closely related to the luminal/UroB tumor subtype of human bladder cancer. MNU-induced bladder tumor in rats offers a good experimental platform that mimics a subset of human bladder cancer in immunocompetent environment. . 199, No. 4S, Supplement, Sunday, May 20, 2018 
